US6559160B1
(en)
|
1999-08-27 |
2003-05-06 |
Chemocentryx, Inc. |
Compounds and methods for modulating cxcr3 function
|
US20070021493A1
(en)
|
1999-09-16 |
2007-01-25 |
Curis, Inc. |
Mediators of hedgehog signaling pathways, compositions and uses related thereto
|
US7230000B1
(en)
|
1999-10-27 |
2007-06-12 |
Cytokinetics, Incorporated |
Methods and compositions utilizing quinazolinones
|
US6545004B1
(en)
*
|
1999-10-27 |
2003-04-08 |
Cytokinetics, Inc. |
Methods and compositions utilizing quinazolinones
|
US7671200B2
(en)
|
1999-10-27 |
2010-03-02 |
Cytokinetics, Inc. |
Quinazolinone KSP inhibitors
|
US8852937B2
(en)
|
2000-03-30 |
2014-10-07 |
Curis, Inc. |
Small organic molecule regulators of cell proliferation
|
US7115653B2
(en)
|
2000-03-30 |
2006-10-03 |
Curis, Inc. |
Small organic molecule regulators of cell proliferation
|
US6667300B2
(en)
|
2000-04-25 |
2003-12-23 |
Icos Corporation |
Inhibitors of human phosphatidylinositol 3-kinase delta
|
CN1575177A
(zh)
*
|
2000-12-11 |
2005-02-02 |
图拉里克公司 |
Cxcr3拮抗剂
|
US6992082B2
(en)
|
2001-01-19 |
2006-01-31 |
Cytokinetics, Inc. |
Phenothiazine kinesin inhibitors
|
US6809102B2
(en)
|
2001-03-29 |
2004-10-26 |
Bristol-Myers Squibb Company |
Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
|
US6900214B2
(en)
|
2001-03-29 |
2005-05-31 |
Bristol-Myers Squibb Company |
Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
|
US6794379B2
(en)
|
2001-06-06 |
2004-09-21 |
Tularik Inc. |
CXCR3 antagonists
|
JP2004534822A
(ja)
|
2001-06-22 |
2004-11-18 |
ファイザー・プロダクツ・インク |
低溶解度および/または酸感受性の薬剤と中和された酸性ポリマーとを含む医薬組成物
|
EP2329822A1
(de)
|
2001-09-05 |
2011-06-08 |
Minerva Biotechnologies Corporation |
Zusammensetzungen und deren Verwendung zur Behandlung von Krebs
|
JP2005511581A
(ja)
|
2001-11-07 |
2005-04-28 |
メルク エンド カムパニー インコーポレーテッド |
有糸分裂キネシン阻害剤
|
US7053216B2
(en)
|
2001-11-19 |
2006-05-30 |
Iconix Pharmaceuticals, Inc. |
Modulators of Rho C activity
|
US6753428B2
(en)
|
2001-11-20 |
2004-06-22 |
Cytokinetics, Inc. |
Process for the racemization of chiral quinazolinones
|
CA2467722A1
(en)
*
|
2001-12-06 |
2003-06-19 |
Merck & Co., Inc. |
Thienopyrimidinone derivatives as mitotic kinesin inhibitors
|
US7262186B2
(en)
|
2001-12-06 |
2007-08-28 |
Merck & Co., Inc. |
Substituted pyrazolo[3,4-d] pyrimidinones as a mitotic kinesin inhibitor
|
ATE424388T1
(de)
|
2001-12-06 |
2009-03-15 |
Merck & Co Inc |
Mitotische kinesinhemmer
|
US7262187B2
(en)
|
2001-12-06 |
2007-08-28 |
Merck & Co., Inc. |
Substituted oxazolo- and thizaolopyrimidinones as a mitotic kinesin inhibitor
|
WO2003050122A2
(en)
|
2001-12-06 |
2003-06-19 |
Merck & Co., Inc. |
Mitotic kinesin inhibitors
|
DK1454903T3
(da)
|
2001-12-11 |
2010-11-22 |
Kyowa Hakko Kirin Co Ltd |
Thiadiazolinderivater til behandling af cancer
|
CA2485148A1
(en)
*
|
2002-05-09 |
2003-11-20 |
Cytokinetics, Inc. |
Pyrimidinone compounds, compositions and methods
|
CA2486215A1
(en)
*
|
2002-06-14 |
2003-12-24 |
Merck & Co., Inc. |
Mitotic kinesin inhibitors
|
EP1539727B1
(de)
*
|
2002-07-17 |
2009-02-18 |
Cytokinetics, Inc. |
Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
|
WO2004055008A1
(en)
*
|
2002-12-13 |
2004-07-01 |
Smithkline Beecham Corporation |
Compounds, compositions and methods
|
US20040242566A1
(en)
*
|
2003-03-25 |
2004-12-02 |
Syrrx, Inc. |
Dipeptidyl peptidase inhibitors
|
WO2004092123A2
(en)
*
|
2003-04-10 |
2004-10-28 |
Microbia, Inc. |
Inhibitors of fungal invasion
|
ES2394850T3
(es)
*
|
2003-04-18 |
2013-02-06 |
Kyowa Hakko Kirin Co., Ltd. |
Inhibidor de cinesina mitótica
|
PT1636225E
(pt)
|
2003-06-20 |
2010-05-03 |
Novartis Vaccines & Diagnostic |
Compostos piridino[1,2-a]pirimidin-4-ona como agentes anti-cancerígenos
|
CA2533889A1
(en)
*
|
2003-08-15 |
2005-03-03 |
Merck & Co., Inc. |
Mitotic kinesin inhibitors
|
US7939539B2
(en)
*
|
2003-11-25 |
2011-05-10 |
Novartis Vaccines And Diagnostics, Inc. |
Quinazolinone compounds as anticancer agents
|
US7439254B2
(en)
*
|
2003-12-08 |
2008-10-21 |
Cytokinetics, Inc. |
Compounds, compositions, and methods
|
US7662581B1
(en)
|
2003-12-18 |
2010-02-16 |
Novartis Vaccines And Diagnostics, Inc. |
Eg5 co-crystals
|
WO2005060654A2
(en)
|
2003-12-19 |
2005-07-07 |
Merck & Co., Inc. |
Mitotic kinesin inhibitors
|
WO2005061707A1
(ja)
*
|
2003-12-24 |
2005-07-07 |
Kyowa Hakko Kogyo Co., Ltd. |
癌細胞のEg5阻害剤に対する感受性を判定する方法
|
WO2005092011A2
(en)
*
|
2004-03-22 |
2005-10-06 |
Merck & Co., Inc. |
Mitotic kinesin inhibitors
|
WO2005095360A1
(en)
|
2004-04-02 |
2005-10-13 |
Prana Biotechnology Limited |
Neurologically-active compounds
|
RS55551B1
(sr)
*
|
2004-05-13 |
2017-05-31 |
Icos Corp |
Hinazolinoni kao inhibitori humane fosfatidilinozitol 3-kinaze delta
|
DK1753723T3
(da)
|
2004-05-21 |
2008-10-20 |
Novartis Vaccines & Diagnostic |
Substituerede quinolinderivater som mitotiske kinesininhibitorer
|
EP1755609A1
(de)
*
|
2004-05-25 |
2007-02-28 |
Icos Corporation |
Verfahren zur behandlung und/oder prävention von überschiessender proliferation von hämatopoetischen zellen
|
BRPI0510929A
(pt)
|
2004-06-18 |
2007-07-17 |
Chiron Corp |
derivados de n-(1-(1-benzil-4-fenil-1h-imidazol-2-il)-2,2-dimetilpropil) benzamida e compostos relacionados como inibidores de proteìna de eixo de kinesin (ksp) para o tratamento de cáncer
|
US7939538B2
(en)
|
2004-06-28 |
2011-05-10 |
Amgen Inc. |
Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases
|
US7375102B2
(en)
|
2004-06-28 |
2008-05-20 |
Amgen Sf, Llc |
Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use
|
US7271271B2
(en)
|
2004-06-28 |
2007-09-18 |
Amgen Sf, Llc |
Imidazolo-related compounds, compositions and methods for their use
|
KR20070046176A
(ko)
|
2004-08-18 |
2007-05-02 |
아스트라제네카 아베 |
특정 융합 피리미돈의 거울상이성질체 및 이의 암 치료 및예방에 있어서의 용도
|
EP1811844A4
(de)
*
|
2004-09-14 |
2009-12-02 |
Minerva Biotechnologies Corp |
Verfahren zur diagnose und behandlung von krebs
|
EP1807399A2
(de)
|
2004-10-19 |
2007-07-18 |
Novartis Vaccines and Diagnostics, Inc. |
Indol- und benzimidazolderivate
|
EP1856128A4
(de)
*
|
2005-01-19 |
2009-12-23 |
Merck & Co Inc |
Inhibitoren von mitotischem kinesin
|
DE102005011822A1
(de)
*
|
2005-03-15 |
2006-09-21 |
Merck Patent Gmbh |
Phthalazinone
|
US7910611B2
(en)
|
2005-06-24 |
2011-03-22 |
Kyowa Hakko Kirin Co., Ltd. |
Therapeutic agent for restenosis
|
MY147188A
(en)
*
|
2005-08-09 |
2012-11-14 |
Novartis Ag |
Substituted imidazole compounds as ksp inhibitors
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
US8173629B2
(en)
|
2006-09-22 |
2012-05-08 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
EP2073807A1
(de)
|
2006-10-12 |
2009-07-01 |
Astex Therapeutics Limited |
Pharmazeutische kombinationen
|
US8916552B2
(en)
|
2006-10-12 |
2014-12-23 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
WO2008057468A1
(en)
|
2006-11-02 |
2008-05-15 |
Curis, Inc. |
Small organic molecule regulators of cell proliferation
|
US8129358B2
(en)
|
2006-11-13 |
2012-03-06 |
Novartis Ag |
Substituted pyrazole and triazole compounds as KSP inhibitors
|
US7820646B2
(en)
|
2007-01-05 |
2010-10-26 |
Novartis Vaccines And Diagnostics, Inc. |
Cyclized derivatives as Eg-5 inhibitors
|
RS58936B1
(sr)
|
2007-01-10 |
2019-08-30 |
Msd Italia Srl |
Indazoli supstituisani amidom kao inhibitori poli(adp-riboza)polimeraze (parp)
|
CA2679659C
(en)
|
2007-03-01 |
2016-01-19 |
Novartis Ag |
Pim kinase inhibitors and methods of their use
|
EP2152700B1
(de)
|
2007-05-21 |
2013-12-11 |
Novartis AG |
Csf-1r-hemmer, zusammensetzungen und anwendungsverfahren
|
EP2173724B1
(de)
|
2007-06-22 |
2012-12-05 |
ArQule, Inc. |
Chinazolinonverbindungen und verfahren zu ihrer anwendung
|
US8389553B2
(en)
|
2007-06-27 |
2013-03-05 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
US9492449B2
(en)
|
2008-11-13 |
2016-11-15 |
Gilead Calistoga Llc |
Therapies for hematologic malignancies
|
US20100202963A1
(en)
|
2008-11-13 |
2010-08-12 |
Gallatin W Michael |
Therapies for hematologic malignancies
|
BR112012001325A2
(pt)
|
2009-07-21 |
2017-05-02 |
Gilead Calistoga Llc |
tratamento de distúrbios do fígado com inibidaores de pi3k
|
WO2012018754A2
(en)
|
2010-08-02 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US9029341B2
(en)
|
2010-08-17 |
2015-05-12 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
|
EP2608669B1
(de)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
Neue pyrazolo-[1,5-a-]pyrimidinderivate als mtor-hemmer
|
US9242981B2
(en)
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
US9260471B2
(en)
|
2010-10-29 |
2016-02-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
|
US20140045847A1
(en)
|
2011-04-21 |
2014-02-13 |
Piramal Enterprises Limited |
Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
|
MX2014010656A
(es)
|
2012-03-05 |
2015-03-03 |
Gilead Calistoga Llc |
Formas polimorficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluo ro-3-fenilquinazolin-4(3h)-ona.
|
EP3453762B1
(de)
|
2012-05-02 |
2021-04-21 |
Sirna Therapeutics, Inc. |
Sina-zusammensetzungen
|
JP6207100B2
(ja)
|
2012-12-21 |
2017-10-04 |
ギリアード カリストガ エルエルシー |
イソキノリノンまたはキナゾリノンホスファチジルイノシトール3−キナーゼ阻害剤
|
BR112015014585A2
(pt)
|
2012-12-21 |
2017-07-11 |
Gilead Calistoga Llc |
composto, composição farmacêutica, e, método de tratamento de um ser humano
|
EA028319B1
(ru)
|
2013-06-14 |
2017-11-30 |
Джилид Калистога Ллс |
Ингибиторы фосфатидилинозитол-3-киназы
|
EP3041938A1
(de)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Kreisförmige polynukleotide
|
EP3083623A1
(de)
|
2013-12-20 |
2016-10-26 |
Gilead Calistoga LLC |
Polymorphe formen eines hydrochloridsalzes aus (s)-2-(9h-purin-6-ylamino)propyl)-5-fluor-3-phenylchinazolin-4 (3h)-on
|
AU2014364410B2
(en)
|
2013-12-20 |
2017-11-16 |
Gilead Calistoga Llc |
Process methods for phosphatidylinositol 3-kinase inhibitors
|
NZ726360A
(en)
|
2014-06-13 |
2018-04-27 |
Gilead Sciences Inc |
Phosphatidylinositol 3-kinase inhibitors
|
SG11201610095SA
(en)
|
2014-06-13 |
2016-12-29 |
Gilead Sciences Inc |
Phosphatidylinositol 3-kinase inhibitors
|
AU2015274626C1
(en)
|
2014-06-13 |
2018-08-09 |
Gilead Sciences, Inc. |
Quinazolinone derivatives as phosphatidylinositol 3-kinase inhibitors
|
WO2015191745A1
(en)
|
2014-06-13 |
2015-12-17 |
Gilead Sciences, Inc. |
Phosphatidylinositol 3-kinase inhibitors
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
US9957267B2
(en)
|
2015-07-01 |
2018-05-01 |
Crinetics Pharmaceuticals, Inc. |
Somatostatin modulators and uses thereof
|
TW201825465A
(zh)
|
2016-09-23 |
2018-07-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
TW201815787A
(zh)
|
2016-09-23 |
2018-05-01 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
TW201813963A
(zh)
|
2016-09-23 |
2018-04-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
EP3658560A4
(de)
|
2017-07-25 |
2021-01-06 |
Crinetics Pharmaceuticals, Inc. |
Somatostatinmodulatoren und verwendungen davon
|
CN111189935A
(zh)
*
|
2019-12-30 |
2020-05-22 |
卓和药业集团有限公司 |
盐酸右美托咪定的高效液相色谱分析方法
|